⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9007545 | 1.00 | GRM5 (0.48) | — | |
| SCHEMBL2684 | 0.97 | — | — | |
| SCHEMBL29472848 | 0.97 | — | — | |
| SCHEMBL29599136 | 0.97 | KDM4E (0.50) | — | |
| SCHEMBL4733426 | 0.97 | KDM4E (0.50) | — | |
| SCHEMBL16322907 | 0.97 | KDM4E (0.50) | — | |
| SCHEMBL25382981 | 0.94 | — | — | |
| SCHEMBL21274595 | 0.94 | — | — | |
| SCHEMBL19540310 | 0.94 | GRM5 (0.48) | — | |
| Hydrochloric Acid SCHEMBL21723652 | 0.94 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 312 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108289922-A | Therapeutic methods and compositions for treating non-small cell lung cancer | 友杏生技医药股份有限公司 | 2018-07-17 | — | — | CN | claimed |
| CN-101775040-B | Process for preparing picoplatin | NANJING CUCCESS PHARMACEUTICAL CO LTD | 2012-05-09 | — | — | CN | claimed |
| CN-101775040-A | New method for preparing picoplatin | NANJING CUCCESS PHARMACEUTICAL | 2010-07-14 | — | — | CN | claimed |
| CN-101056620-A | Method of treating cancer by intraperitoneal administration of lipid-based platinum compound preparation | TRANSAVE INC (US) | 2007-10-17 | — | — | CN | claimed |
| CN-112955178-B | Combination of LIF inhibitor and platinum-based antitumor agent for the treatment of cancer | 免疫医疗有限公司 | 2025-03-11 | — | — | CN | disclosed |
| CN-118267470-A | Anti-SIRP alpha antibodies | 赛罗帕私人有限公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-117924486-A | Anti-CD 27 antibodies | 默沙东有限责任公司 | 2024-04-26 | — | — | CN | disclosed |
| CN-110650976-B | Anti-SIRP alpha antibodies | 赛罗帕私人有限公司 | 2024-04-19 | — | — | CN | disclosed |
| CN-115003303-B | PRMT5 inhibitors | 默沙东公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-115087638-B | PRMT5 inhibitors | 默沙东公司 | 2023-11-24 | — | — | CN | disclosed |
| CN-109890846-B | anti-CD 27 antibodies | 默沙东有限责任公司 | 2023-10-24 | — | — | CN | disclosed |
| CN-110996958-B | Stable lyophilisates comprising 5, 10-methylene- (6R) -tetrahydrofolate and dicarboxylic acids | 默克专利股份有限公司 | 2023-05-12 | — | — | CN | disclosed |
| US-20050026896-A1 | Platinum(II) and platinum(IV) complexes and their use | FAUSTUS FORSCHUNGS CIE. TRANSLATIONAL CANCER RESEARCH GMBH | 2005-02-03 | — | — | US | disclosed |
| WO-2004109290-A2 | METHODS FOR IDENTIFYING MODULATORS OF KINESIN ACTIVITY | ROSETTA INPHARMATICS LLC (US) | 2004-12-16 | — | — | WO | disclosed |
| EP-1419166-A2 | PLATINUM(II)- AND PLATINUM(IV)-COMPLEXES AND THEIR USE | Faustus Forschungs Cie. Translational Cancer Research GmbH (DE) | 2004-05-19 | — | — | EP | disclosed |
| WO-2003106417-A1 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2003-12-24 | — | — | WO | disclosed |
| CN-1430515-A | Combination therapy with vascular damaging activity | ANGLOGENE PHARMACEUTICALS LTD (GB) | 2003-07-16 | — | — | CN | disclosed |
| CN-1409708-A | Tyrosine kinase inhibitors | MERCK & CO INC (US) | 2003-04-09 | — | — | CN | disclosed |
| WO-2003018593-A2 | PLATINUM(II)- AND PLATINUM(IV)-COMPLEXES AND THEIR USE | FAUSTUS FORSCHUNGS CIE. TRANSLATIONAL CANCER RESEARCH GMBH (DE) | 2003-03-06 | — | — | WO | disclosed |
| CN-1390215-A | Tyrosine kinase inhibitors | MERCK & CO INC (US) | 2003-01-08 | — | — | CN | disclosed |